Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The T-cell receptor CD3 zeta chain (CD3ζ) is a critical component of the TCR/CD3 complex on T lymphocytes, required for TCR expression, stability, and signal transduction. It forms ζζ homodimers that partner with other CD3 subunits (CD3δ, CD3γ, and CD3ε), embedding three ITAMs within its intracellular domain. Upon antigen recognition by the TCR, these ITAM motifs initiate downstream signaling by recruiting kinases such as LCK and ZAP-70, leading to T cell activation. Loss or diminished expression of CD3ζ results in impaired TCR transport, degradation of incomplete receptor complexes, and decreased function of T cells. Therapeutically, CD3ζ is targeted to modulate immune responses in contexts ranging from cancer immunotherapy to transplantation.
Immunomodulation — Monoclonal antibodies such as muromonab-CD3 bind the CD3 complex (including CD3ζ), resulting in T cell depletion or modulation via activation-induced apoptosis or anergy. Signal enhancement — Genetic enhancement or supplementation of CD3ζ in engineered T cells increases TCR surface expression and improves antigen-specific function.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell receptor CD3 zeta chain (CD3ζ).